Objective-To investigate variations in the management of patients with atrial fibrillation among consultant physicians. Design-Questionnaire survey. Subjects-Consultant physicians in England, Wales, and Scotland. Results-214 consultant physicians (88 cardiologists and 126 non-cardiologists) were surveyed between May and July 1994. Most physicians (47.7%) reported that they saw one to five patients with atrial fibrillation weekly. Some 52% of cardiologists and 40% of non-cardiologists considered that the main factor influencing their decision of whether or not to anticoagulate was the clinical history--that is, heart failure, valve disease, or stroke.
(86% v 69%, x2 = 11-75 P = 0.003) cardioversion to sinus rhythm, while noncardiologists tended to prefer "rate control" with digoxin. Although many physicians would not continue antiarrhythmic treatment post-cardioversion, more cardiologists than non-cardiologists would do so (the commonest choice being class III agents) (31% v 17%, P = 0.04).
Fewer non-cardiologists would continue anticoagulant treatment post-cardioversion (27% v 69% of cardiologists, X2 = 39-85 P < 0.0001). When treating patients with atrial fibrillation, decisions about anticoagulation were usually related to the perceived relative risk of thromboembolism versus haemorrhage derived for each of six case management scenarios in the questionnaire. There was, however, general agreement between cardiologists and non-cardiologists in the use of antithrombotic treatment in the management of lone atrial fibrillation, paroxysmal atrial fibrillation, and patients with atrial fibrillation and mitral valve disease or thyrotoxicosis.
Conclusion-There is considerable variation in the management of atrial fibrillation, with more cardiologists than non-cardiologists considering cardioversion to sinus rhythm (and the use of antiarrhythmic and anticoagulant treatment post-cardioversion) and thromboprophylaxis with anticoagulation. Guidelines on the management of this common arrhythmia are clearly required. (Heart 1996; 75:200-205) Keywords: atrial fibrillation; physician variation; questionnaire survey Atrial fibrillation is a common arrhythmia with different aetiologies, clinical presentations, and therapeutic options. Ideally, the management of atrial fibrillation should follow three phases: a search for an underlying cause with appropriate investigations; control of the arrhythmia and the reduction of thromboembolic risk; and finally, consideration of cardioversion to sinus rhythm.
We have observed that there are wide variations in management strategies of this common arrhythmia. In a recent prospective survey of acute admissions with atrial fibrillation to a district general hospital, there was suboptimal application of standard investigations, a reluctance to start anticoagulant treatment, or to consider electrical or pharmacological cardioversion.1 In addition, retrospective studies have shown that many patients with atrial fibrillation were not receiving anticoagulation despite the absence of contraindications. '3 The variations in investigations, therapeutic use of antiarrhythmic treatment, and prophylactic use of anticoagulant treatment may be a reflection of a lack of consensus on the optimal management of atrial fibrillation among physicians. For example, in a survey of 134 clinicians Chang et al 4 reported considerable variation in the use of anticoagulant treatment in atrial fibrillation. However, that survey was published before the publication of several large randomised controlled trials of the use of warfarin or aspirin, or both, as thromboprophylaxis against stroke in patients with atrial fibrillation. [5] [6] [7] To investigate further the extent of variation in management of atrial fibrillation and to determine whether clinicians make treatment Most physicians (47 7%) reported that they saw one to five patients with atrial fibrillation weekly, although cardiologists tended to see more. When asked to state which was the most important factor influencing their decision of whether or not to anticoagulate a patient with atrial fibrillation, 52% of cardiologists and 40% of non-cardiologists considered that the main factor was the clinical history (that is, heart failure, valve disease, or stroke), while the next most important factors were the presence of contraindications to warfarin and information obtained from echocardiography (table 2) .
When encountering a patient admitted acutely with new onset atrial fibrillation, most physicians would start anticoagulant treatment, although more cardiologists than noncardiologists would do so (66% v 52%, x2 = 6-89, P = 0 03). Most cardiologists (two thirds) would start with intravenous heparin. By contrast, more non-cardiologists reported the use of either intravenous or subcutaneous heparin, or warfarin (table 2) .
Most physicians would immediately introduce antiarrhythmic drug treatment, with digoxin being the most popular choice. However, more cardiologists would attempt immediate pharmacological (39% v 18% of non-cardiologists, X2 = 11-3, df = 1, P < 0 001 or later electrical (86% v 69%, %2 = 11-7, P = 0 003) cardioversion to sinus rhythm, while non-cardiologists tended to prefer "rate control" with digoxin ( When approaching a patient with atrial fibrillation, the decision arises of whether or not to attempt cardioversion to sinus rhythm or to achieve rate control of the arrhythmia and provide adequate thromboprophylaxis. In the present survey, the factors that most influenced the physician's decision of whether or not to anticoagulate were the clinical history (especially a history of heart failure, stroke, mitral valve disease, or hypertension), the presence of contraindications to anticoagulants, and information obtained from echocardiography. This opinion is therefore consistent with data from the stroke prevention in atrial fibrillation study9 in which the three independent clinical predictors of an increased risk of stroke were: (i) a history of hypertension; (ii) recent (within 3 months) congestive heart failure; and (iii) previous cerebrovascular event (either stroke or transient ischaemic attack). Risk stratification on the basis of these three factors allowed identification of three rates of arterial thromboembolism: 2-5% (for patients with no risk factors), 7-2%/year (if one risk factor was present), and 17-6%/year (if two or three risk factors were present).9
Echocardiography is also an important investigation in patients with atrial fibrillation, especially in the assessment of risk of stroke and thromboembolism. For example, echocardiographic data from the stroke prevention in atrial fibrillation study'0 showed that left ventricular dysfunction (on the two dimensional echocardiogram) and the size of the left atrium (from M mode echocardiograms) were strong independent predictors of later thromboembolism in patients with atrial fibrillation. In an audit of hospital management of this arrhythmia, however, this investigation was performed in only about one third of patients with atrial fibrillation, even though useful information was found in most patients undergoing echocardiography. I Some differences were apparent in the approach to the management of a patient newly presenting with atrial fibrillation. Although most physicians would start anticoagulation, cardiologists were more likely to do so, with many favouring immediate intravenous heparin. The immediate anticoagulation would provide prophylaxis against the increased risk of thromboembolism, which is prevalent around the time of onset of atrial fibrillation."-'3 Full anticoagulation with intravenous heparin (achieving a partial thromboplastin time ratio of 2 0-3 0) would probably be the regimen of choice, as it works rapidly, can be closely monitored, and where necessary, can be discontinued quickly; in addition, oral warfarin (if needed) could be prescribed concurrently. In comparison, administration of warfarin alone to a patient newly presenting with atrial fibrillation would require at least 72 h to achieve adequate anticoagulation. The use of subcutaneous heparin, especially at a dose of 5000 IU three times daily, may be inadequate as thromboprophylaxis.'4 15 By contrast, the use of subcutaneous heparin at a dose of 12 500 IU twice daily reduces mural thrombus and embolism in patients after anterior myocardial infarction,15 although the benefits in patients with atrial fibrillation are unknown. The anticoagulant effect with subcutaneous heparin may be inconsistent, however, dependent on the pharmacokinetics in the individual patient. '4 Most physicians in this survey would also introduce antiarrhythmic treatment to a patient newly presenting with atrial fibrillation. Although most physicians favoured "rate control", more cardiologists would give antiarrhythmic treatment with the aim of immediate pharmacological cardioversion. Most cardiologists and physicians would arrange electrical cardioversion to sinus rhythm if the patient persisted in atrial fibrillation despite antiarrhythmic treatment; however, up to 25% of non-cardiologists said they would not do so. Consideration of suitable patients with atrial fibrillation for cardioversion is important, in view of the haemodynamic benefits of returning to normal sinus rhythm. In addition, the chances of successful cardioversion diminish with increasing duration of atrial fibrillation if the procedure is not considered. '6 Many physicians do not routinely continue with antiarrhythmic drug treatment to maintain sinus rhythm if cardioversion is successful; however, more cardiologists than non-cardiologists would use postcardioversion antiarrhythmic treatment (especially with class III agents). There is a high risk of relapse of atrial fibrillation without antiarrhythmic drugs, with the proportion remaining in sinus rhythm ranging from 69% at 1 month to 58% at 6 months, 23% at 1 year, and 16% at 2 years.'7 In the present survey, the commonest duration of continuing post-cardioversion antiarrhythmic treatment among cardiologists was for 6 months or more. Recent recommendations suggest that the use of antiarrhythmic drug treatment was most beneficial for 3 months post-cardioversion.'8 However, many non-cardiologists in the present survey did not provide an answer to this question, perhaps reflecting the paucity of data on the optimal duration of continuing antiarrhythmic treatment after cardioversion to maintain sinus rhythm.
This survey also demonstrates that most cardiologists and few non-cardiologists would continue anticoagulant treatment after cardioversion to sinus rhythm, usually for 1-3 months. The finding has important implications, as the risk of thromboembolism probably continues even after successful cardioversion, as atrial mechanical function may not be restored for several weeks. '9 20 However, the optimal duration of anticoagulation is, as yet, unclear. Recent recommendations by the American College of Chest Physicians include: (i) administration of warfarin for 3 weeks before elective cardioversion of atrial fibrillation of > 3 days' duration; (ii) continuation of warfarin for 2-4 weeks after cardioversion; (iii) administration of intravenous heparin followed by warfarin if cardioversion cannot be postponed for 3 weeks; and (iv) no anticoagulant treatment for atrial fibrillation of <2 days' duration or atrial flutter.2' It may be prudent to continue anticoagulation for longer than 4 weeks in patients with a high risk of recurrent atrial fibrillation.
The REs and RHs estimated by physicians in this survey were generally much higher than those reported for the individual conditions. The probability of stroke and thromboembolism in patients with non-valvular atrial fibrillation who are not receiving warfarin, is about 5%/year, while the risk of bleeding with warfarin is 1%/year. This risk is increased by the presence of structural heart disease and poor left ventricular function, as discussed earlier.9 Remarkably, physicians in this survey also tended to overestimate the risk of thromboembolism in patients with lone atrial fibrillation. In the study by Kopecky et al122 only 1-3% of healthy patients with lone atrial fibrillation had thromboembolism over 15 years. By contrast, data from the Framingham study23 suggested a fivefold increase in risk for stroke in patients with lone atrial fibrillation, although patients in that study were older. 23 Warfarin (as discussed earlier) reduces the risk of stroke and thromboembolism by two thirds, but increases bleeding by 53%24 (or 0-5%/year). As the initial risk of bleeding is fivefold smaller than the risk of embolism, prophylaxis with warfarin should be given unless it is considered that the risk of bleeding is perceived to be over six times more detrimental than the risk of thromboembolism.24 Possible factors that may increase the risk of bleeding with warfarin include:5 age, uncontrolled hypertension (defined as systolic blood pressure > 180 mm Hg or diastolic blood pressure > 100 mm Hg), alcohol excess, liver disease, poor drug or clinical compliance, and bleeding lesions (especially gastrointestinal blood loss, for example, peptic ulcer disease, or previous cerebral haemorrhage), or bleeding tendency (including coagulation defects and thrombocytopenia). Concomitant use of aspirin with oral anticoagulants also increases the risk of bleeding. These factors therefore need to be taken into consideration when the risk of haemorrhage in patients given warfarin is evaluated.
The perceived relative risks of thromboembolism versus haemorrhage (RE/RH) in different case scenarios did not differ significantly between cardiologists and non-cardiologists. However, the decision of whether or not to anticoagulate was related to risk estimates. This reassuring observation suggests that physicians make management decisions about anticoagulation of patients with atrial fibrillation based on risk estimates.
In conclusion, this survey suggests that considerable variation in the management of atrial fibrillation remains, with more cardiologists than non-cardiologists considering anticoagulation or cardioversion to sinus rhythm (and the use of antiarrhythmic and anticoagulant treatment post-cardioversion). Up to date guidelines on the management of this common arrhythmia are clearly required. 
